XENON PHARMACEUTICALS

🇮🇳India

Country: 🇮🇳India

Ownership: -

Established: 1996-01-01

Employees: -

Market Cap: $3.1B

Website: http://www.xenon-pharma.com/

Clinical Trials

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: XEN901
Drug: Inert Ingredients Oral Product

First Posted Date: 2018-03-15

Last Posted Date: 2019-07-22

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 70

Registration Number: NCT03467100

Locations: 🇬🇧
Quotient Sciences, Ruddington, United Kingdom

Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of XEN1101.

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: XPF-010
Drug: XPF-008
Drug: Itraconazole 400mg
Drug: Microcrystalline Cellulose

First Posted Date: 2017-11-13

Last Posted Date: 2023-05-11

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 130

Registration Number: NCT03340220

Locations: 🇬🇧
Richmond Pharmacology Ltd., London, United Kingdom

A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel

Phase 1

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Placebo
Drug: XPF-005

First Posted Date: 2016-01-14

Last Posted Date: 2019-01-22

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 213

Registration Number: NCT02656043

Locations: 🇨🇦
Lynderm Research Inc, Markham, Ontario, Canada
🇨🇦
Toole Dermatology Research, Winnipeg, Manitoba, Canada
🇨🇦
Windsor Clinical Research Inc., Windsor, Ontario, Canada

and more 17 locations

Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia

Phase 1

Completed

Conditions: Inherited Erythromelalgia
Primary Erythromelalgia

Interventions: Drug: XPF-002
Drug: Placebo

First Posted Date: 2011-12-06

Last Posted Date: 2014-04-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT01486446

Locations: 🇺🇸
Pinnacle Research Group, LLC., Anniston, Alabama, United States

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

Phase 2

Completed

Conditions: Postherpetic Neuralgia

Interventions: Drug: XPF-002
Drug: Placebo

First Posted Date: 2010-09-06

Last Posted Date: 2013-11-25

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 70

Registration Number: NCT01195636

Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM)

Phase 1

Completed

Conditions: Primary Erythromelalgia
Inherited Erythromelalgia

Interventions: Drug: Placebo
Drug: XPF-001

First Posted Date: 2010-03-22

Last Posted Date: 2012-03-16

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 4

Registration Number: NCT01090622

Locations: 🇳🇱
Clinical Research Centre at Radboud University Nijmegen Medical Center, Nijmegen, Netherlands

Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Phase 2

Completed

Conditions: Dental Pain

Interventions: Drug: placebo
Drug: XPF-001

First Posted Date: 2009-08-07

Last Posted Date: 2012-07-16

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 61

Registration Number: NCT00954356

Locations: 🇺🇸
Jean Brown Research, Salt Lake City, Utah, United States

Single and Multiple Ascending Dose Safety Study of XPF-001 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Human Volunteers

Interventions: Drug: XPF-001

First Posted Date: 2008-12-23

Last Posted Date: 2009-09-14

Lead Sponsor: Xenon Pharmaceuticals Inc.

Target Recruit Count: 64

Registration Number: NCT00813670

Locations: 🇨🇦
Anapharm, Montreal, Quebec, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy